Business
RenovaCare Issues Stern Response to Admitted Short-Seller, Streetsweeper, Affiliated with Felon Convicted of Securities Fraud
RenovaCare Issues Stern Response to Admitted Short-Seller, Streetsweeper, Affiliated with Felon Convicted of Securities Fraud.
About this update from Renovacare, Inc.
[{"type":"text","content":"\n \n RenovaCare, Inc., (OTCQB:RCAR), developer of the SkinGun™ and CellMist™ \n System for isolating and spraying a patient's own stem cells onto burns \n and wounds for rapid self-healing, today issued a strong rejection to \n Streetsweeper, known for spreading “short and distort” commentary on \n companies it targets for short selling, in this case RenovaCare.\n \n\nThis press release features multimedia. View the full release here: \nhttp://www.businesswire.com/news/home/20180212006308/en/\n\n \n \n RenovaCare SkinGun™ Sprays Stem Cells to Heal Burns and Wounds. (Photo: Business Wire)\n \n\n\n \n \"We will not be distracted by the irresponsible and nefarious actions of \n these short sellers and a handful of internet posters,\" stated Mr. \n Thomas Bold, President and CEO of RenovaCare Technologies, Inc. \"We have \n an obligation to expose those who prey on our shareholders for \n short-term profits and attempt to damage the public trust.\"\n \n \n \"Meanwhile, our clinical and regulatory teams continue to make \n incredible strides, with our next major milestone being our initial FDA \n filing. We are determined to bring our breakthrough stem cell therapy to \n market with the ongoing strong support of our shareholders.”\n \n \n To date, over 70 severe burn victims have been treated, with many \n patients discharged in a matter of days because of their rapid recovery.\n \n \n The Company’s technologies have been published in numerous prestigious \n peer-reviewed medical journals; and, RenovaCare has been featured in \n National Geographic, Bloomberg, Forbes and CNN, and its SkinGun™ is \n currently on display at the prestigious Science Museum in London. (Click \n Here To Learn More)\n \n \n The RenovaCare mission is to build shareholder value by advancing its \n much-needed technology through the regulatory process and make its \n products available as quickly as possible to the millions that suffer \n from burns, chronic and acute wounds and scars, a $45 billion market in \n the U.S. alone.\n \n \n *RenovaCare products are currently in development. They are not \n available for sale in the United States. There is no assurance that the \n company’s planned or filed submissions to the U.S. Food and Drug \n Administration, if any, will be accepted or cleared by the FDA.\n...